DCC-2036 inhibits osteosarcoma via targeting HCK and the PI3K/AKT-mTORC1 axis to promote autophagy
Collectively, these findings indicate that DCC-2036 promotes autophagy in osteosarcoma (OS) cells by targeting the HCK/AKT/mTORC1 axis and exerts anti-tumor effects without significant toxicity. Consequently, DCC-2036 emerges as a promising therapeutic agent for the treatment of HCK-overexpressing osteosarcoma.
Authors
- Liyang Yin
- Yingying Shen (ORCID: https://orcid.org/0000-0003-2295-7316)
- Zhongliang Deng (ORCID: https://orcid.org/0000-0002-0978-8178)
- Jun He (ORCID: https://orcid.org/0000-0003-1510-1093)
- Qiong Yuan (ORCID: https://orcid.org/0009-0002-3868-0569)
- Xiaotao Su
Institutions
- Dalian Medical University (CN)
- Second Affiliated Hospital of Chongqing Medical University (CN)
- First Affiliated Hospital of University of South China (CN)
- Chongqing Medical University (CN)
- University of South China (CN)
Publication Details
- Journal
- World Journal of Surgical Oncology
- Published
- 2025-04-02
- DOI
- https://doi.org/10.1186/s12957-025-03778-2
- Citations
- 2
- Primary Topic
- Autophagy in Disease and Therapy
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- Health Commission of Hunan Province
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province